Chromatin remodeling and histone modifications in pituitary tumors

Molecular and Cellular Endocrinology

Volumn 326, Issue 1-2, 2010, Pages 66-70

  Tateno, Toru ^a   Zhu, Xuegong ^a   Asa, Sylvia L ^a   Ezzat, Shereen ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chromatin remodeling; DNA methylation; Epigenetics; FGF; FGF receptors; Histone modifications

Indexed keywords

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; HISTONE; HISTONE DEACETYLASE; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; HISTONE METHYLTRANSFERASE; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 6; UNCLASSIFIED DRUG;

CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CPG ISLAND; DNA DAMAGE; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE REARRANGEMENT; GENE SILENCING; GENOME IMPRINTING; HETEROZYGOSITY LOSS; HUMAN; HYPOPHYSIS TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; MICE; PITUITARY GLAND; PITUITARY NEOPLASMS; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 77955327563     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.12.028     Document Type: Review

References (55)

1. Abbass S.A.A., Asa S.L., Ezzat S. Altered expression of fibroblast growth factor receptors in human pituitary adenomas. J. Clin. Endocrinol. Metab. (Baltimore) 1997, 82:1160-1166.
2. Alexander J.M. Tumor suppressor loss in pituitary tumors. Brain Pathol. 2001, 11:342-355.
3. Asa S.L., Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr. Rev. 1998, 19:798-827.
4. Asa S.L., Ezzat S. The pathogenesis of pituitary tumours. Nat. Rev. Cancer 2002, 2:836-849.
5. Asa S.L., Ezzat S. The pathogenesis of pituitary tumors. Annu. Rev. Pathol. 2009, 4:97-126.
6. Bahar A., Bicknell J.E., Simpson D.J., Clayton R.N., Farrell W.E. Loss of expression of the growth inhibitory gene GADD45gamma, in human pituitary adenomas, is associated with CpG island methylation. Oncogene (Basinstoke) 2004, 23:936-944.
7. Bamberger C.M., Fehn M., Bamberger A.M., Ludecke D.K., Beil F.U., Saeger W., Schulte H.M. Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. Eur. J. Endocrinol. 1999, 140:250-255.
8. Baraniak A.P., Lasda E.L., Wagner E.J., Garcia-Blanco M.A. A stem structure in fibroblast growth factor receptor 2 transcripts mediates cell-type-specific splicing by approximating intronic control elements. Mol. Cell. Biol. 2003, 23:9327-9337.
9. Bates A.S., Farrell W.E., Bicknell E.J., McNicol A.M., Talbot A.J., Broome J.C., Perrett C.W., Thakker R.V., Clayton R.N. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J. Clin. Endocrinol. Metab. (Baltimore) 1997, 82:818-824.
10. Bilodeau S., Vallette-Kasic S., Gauthier Y., Figarella-Branger D., Brue T., Berthelet F., Lacroix A., Batista D., Stratakis C., Hanson J., Meij B., Drouin J. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev. 2006, 20:2871-2886.
11. Celli G., LaRochelle W.J., Mackem S., Sharp R., Merlino G. Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. EMBO J. 1998, 17:1642-1655.
12. De Moerlooze L., Spencer-Dene B., Revest J., Hajihosseini M., Rosewell I., Dickson C. An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development 2000, 127:483-492.
13. Dudley K.J., Revill K., Whitby P., Clayton R.N., Farrell W.E. Genome-wide analysis in a murine Dnmt1 knockdown model identifies epigenetically silenced genes in primary human pituitary tumors. Mol. Cancer Res. 2008, 6:1567-1574.
14. Ezzat S., Asa S.L. Mechanisms of disease: the pathogenesis of pituitary tumors. Nat. Clin. Pract. Endocrinol. Metab. 2006, 2:220-230.
15. Ezzat S., Asa S.L. The emerging role of the Ikaros stem cell factor in the neuroendocrine system. J. Mol. Endocrinol. 2008, 41:45-51.
16. Ezzat S., Mader R., Fischer S., Yu S., Ackerley C., Asa S.L. An essential role for the hematopoietic transcription factor Ikaros in hypothalamic-pituitary-mediated somatic growth. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:2214-2219.
17. Ezzat S., Yu S., Asa S.L. Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5' fibroblast growth factor receptor-4 promoter. Am. J. Pathol. 2003, 163:1177-1184.
18. Ezzat S., Zhu X., Loeper S., Fischer S., Asa S.L. Tumor-derived Ikaros 6 acetylates the Bcl-XL promoter to up-regulate a survival signal in pituitary cells. Mol. Endocrinol. 2006, 20:2976-2986.
19. Ezzat S., Mader R., Yu S., Ning T., Poussier P., Asa S.L. Ikaros integrates endocrine and immune system development. J. Clin. Investig. 2005, 115:1021-1029.
20. Horiguchi K., Yamada M., Satoh T., Hashimoto K., Hirato J., Tosaka M., Yamada S., Mori M. Transcriptional activation of the mixed lineage leukemia-p27Kip1 pathway by a somatostatin analogue. Clin. Cancer Res. 2009, 15:2620-2629.
21. Itoh N., Ornitz D.M. Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004, 20:563-569.
22. Jacks T., Fazeli A., Schmitt E.M., Bronson R.T., Goodell M.A., Weinberg R.A. Effects of an Rb mutation in the mouse. Nature (London) 1992, 359:295-300.
23. Kim J., Reber H.A., Hines O.J., Kazanjian K.K., Tran A., Ye X., Amersi F.F., Martinez S.R., Dry S.M., Bilchik A.J., Hoon D.S. The clinical significance of MAGEA3 expression in pancreatic cancer. Int. J. Cancer (New York) 2006, 118:2269-2275.
24. Kondo T., Zheng L., Liu W., Kurebayashi J., Asa S.L., Ezzat S. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res. 2007, 67:5461-5470.
25. Kondo T., Zhu X., Asa S.L., Ezzat S. The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin. Cancer Res. 2007, 13:4713-4720.
26. Lidhar K., Korbonits M., Jordan S., Khalimova Z., Kaltsas G., Lu X., Clayton R.N., Jenkins P.J., Monson J.P., Besser G.M., Lowe D.G., Grossman A.B. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J. Clin. Endocrinol. Metab. 1999, 84:3823-3830.
27. Lloyd R.V., Cano M., Landefeld T.D. The effects of estrogens on tumor growth and on prolactin and growth hormone mRNA expression in rat pituitary tissues. Am. J. Pathol. 1988, 133:397-406.
28. Loeper S., Asa S.L., Ezzat S. Ikaros modulates cholesterol uptake: a link between tumor suppression and differentiation. Cancer Res. 2008, 68:3715-3723.
29. Luo Y., Ye S., Kan M., McKeehan W.L. Structural specificity in a FGF7-affinity purified heparin octasaccharide required for formation of a complex with FGF7 and FGFR2IIIb. J. Cell. Biochem. 2006, 97:1241-1258.
30. Monte M., Simonatto M., Peche L.Y., Bublik D.R., Gobessi S., Pierotti M.A., Rodolfo M., Schneider C. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:11160-11165.
31. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996, 85:707-720.
32. Ornitz D.M., Zu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F., Gao G., Goldfarb M. Receptor specificity of the fibroblast growth factor family. J. Biol. Chem. 1996, 271:15292-15297.
33. Otte M., Zafrakas M., Riethdorf L., Pichlmeier U., Loning T., Janicke F., Pantel K. MAGE-A gene expression pattern in primary breast cancer. Cancer Res. 2001, 61:6682-6687.
34. Pei L., Melmed S., Scheithauer B., Kovacs K., Benedict W.F., Prager D. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res. (Baltimore) 1995, 55:1613-1616.
35. Qian Z.R., Sano T., Yoshimoto K., Yamada S., Ishizuka A., Mizusawa N., Horiguchi H., Hirokawa M., Asa S.L. Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. Lab. Invest. 2005, 85:464-473.
36. Sasaki S., Lesoon-Wood L.A., Dey A., Kuwata T., Weintraub B.D., Humphrey G., Yang W.M., Seto E., Yen P.M., Howard B.H., Ozato K. Ligand-induced recruitment of a histone deacetylase in the negative-feedback regulation of the thyrotropin beta gene. EMBO J. 1999, 18:5389-5398.
37. Sigalotti L., Fratta E., Coral S., Tanzarella S., Danielli R., Colizzi F., Fonsatti E., Traversari C., Altomonte M., Maio M. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res. 2004, 64:9167-9171.
38. Simpson D.J., Hibberts N.A., McNicol A.M., Clayton R.N., Farrell W.E. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res. (Baltimore) 2000, 60:1211-1216.
39. Thapar K., Scheithauer B.W., Kovacs K., Pernicone P.J., Laws E.R. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery (Baltimore) 1996, 38:765-771.
40. Thisse B., Thisse C. Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev. Biol. 2005, 287:390-402.
41. Thisse B., Thisse C., Weston J.A. Novel FGF receptor (Z-FGFR4) is dynamically expressed in mesoderm and neurectoderm during early zebrafish embryogenesis. Dev. Dyn. 1995, 307.
42. Ushijima T., Watanabe N., Okochi E., Kaneda A., Sugimura T., Miyamoto K. Fidelity of the methylation pattern and its variation in the genome. Genome Res. 2003, 13:868-874.
43. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den E.B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Washington) 1991, 254:1643-1647.
44. Wang J., Scully K., Zhu X., Cai L., Zhang J., Prefontaine G.G., Krones A., Ohgi K.A., Zhu P., Garcia-Bassets I., Liu F., Taylor H., Lozach J., Jayes F.L., Korach K.S., Glass C.K., Fu X.D., Rosenfeld M.G. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature (London) 2007, 446:882-887.
45. Weynants P., Lethe B., Brasseur F., Marchand M., Boon T. Expression of mage genes by non-small-cell lung carcinomas. Int. J. Cancer (New York) 1994, 56:826-829.
46. Wischnewski F., Pantel K., Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol. Cancer Res. 2006, 4:339-349.
47. Woloschak M., Yu A., Xiao J., Post K.D. Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary tumors. Int. J. Cancer (New York) 1996, 67:16-19.
48. Xiao J., Chen H.S. Biological functions of melanoma-associated antigens. World J. Gastroenterol. 2004, 10:1849-1853.
49. Yang B., O'Herrin S., Wu J., Reagan-Shaw S., Ma Y., Nihal M., Longley B.J. Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J. Invest. Dermatol. 2007, 127:267-275.
50. Yu S., Asa S.L., Weigel R.J., Ezzat S. Pituitary tumor AP-2alpha recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4. J. Biol. Chem. 2003, 278:19597-19602.
51. Zhang X., Sun H., Danila D.C., Johnson S.R., Zhou Y., Swearingen B., Klibanski A. Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J. Clin. Endocrinol. Metab. 2002, 87:1262-1267.
52. Zhang Y., Wang H., Toratani S., Sato J.D., Kan M., McKeehan W.L., Okamoto T. Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:11336-11340.
53. Zhao J., Dahle D., Zhou Y., Zhang X., Klibanski A. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J. Clin. Endocrinol. Metab. 2005, 90:2179-2186.
54. Zhu X., Lee K., Asa S.L., Ezzat S. Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am. J. Pathol. 2007, 170:1618-1628.
55. Zhu X., Mao X., Hurren R., Schimmer A.D., Ezzat S., Asa S.L. Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells. J. Clin. Endocrinol. Metab. 2008, 93:3610-3617.